Science News
Stay updated with the latest scientific news and research. Read press releases covering groundbreaking discoveries, innovations, and developments across various scientific fields. Keep up with the advancements and insights shaping the future of science.
Nov 20, 2026 at 4:04 PM
AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Wednesday, December 2, 2026 at 8:20am ET and members of management will be available for 1x1 meetin...
Nov 20, 2026 at 4:01 PM
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the company will participate in the following investor conferences:Evercore 9th Annual Healthcare Conference at The Loews Coral Gables Hotel in Coral Gables, FL. Fireside chat on Tuesday, December 1, 2026, at 1:45pm ET.Piper Sandler 38th Annual Healthcare Conference at the Lotte New York Palace in New York, NY. Fire...
Nov 20, 2026 at 2:54 PM
Donaldson Company Declares Quarterly Cash Dividend
MINNEAPOLIS--(BUSINESS WIRE)--Donaldson Company, Inc. (NYSE: DCI) today announced its Board of Directors declared a regular cash dividend of 32.0 cents per share. The dividend is payable December 22nd, 2026, to shareholders of record on December 9th, 2026. Donaldson is a member of the S&P High-Yield Dividend Aristocrats Index and calendar year 2025 marked the 30th consecutive year of annual dividend increases. The Company has paid a cash dividend every quarter for 70 years.About Donaldson Co...
Nov 20, 2026 at 12:40 PM
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope
GOTHENBURG, Sweden--(BUSINESS WIRE)--Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectr...
Nov 20, 2026 at 10:03 AM
Chattanooga Quantum Collaborative, The Company Lab, and Outset Ventures Join Forces to Accelerate Quantum Commercialization
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--A new Tennessee-New Zealand partnership gives quantum startups a pathway to commercial infrastructure, enterprise customers and global capital....
Nov 20, 2026 at 9:00 AM
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership
NEW YORK--(BUSINESS WIRE)--ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potentia...
Nov 20, 2026 at 7:30 AM
Fujifilm Expands ECHELON Synergy 1.5T MRI with ZeroHelium Technology and Dockable Patient Table Option
LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announces the latest evolution of its ECHELON Synergy 1.5T magnetic resonance imaging (MRI) platform. The new release expands customer choice with the availability of ECHELON Synergy ZeroHelium system, designed to operate without liquid helium while delivering high-quality imaging, intelligent workflow and patient-focused design. Fujifilm will showcase...
Nov 20, 2026 at 7:01 AM
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award...
Nov 20, 2026 at 6:48 AM
Alterome Therapeutics Presents Preliminary Clinical Data from Ongoing Phase 1/1b Trial of ALTA3263 Demonstrating Antitumor Activity in KRAS-Mutant Colorectal and Pancreatic Cancers at the 38th EORTC-NCI-AACR Symposium
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers, today announced the presentation of the preliminary clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor, in adult patients with KRAS-mutant advanced...
Nov 20, 2026 at 6:45 AM
Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
RAHWAY, N.J.--(BUSINESS WIRE)--TroFuse-015 Evaluating Sac-TMT Met Primary Endpoint of OS in 3rd-Line or Later Locally Adv. Unresectable or Metastatic Gastroesophageal Adenocarcinoma...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.